Table 1.
AL | ASAQ | MQAS | DHAPQ | p-valuea | |||||
---|---|---|---|---|---|---|---|---|---|
N | N | N | N | ||||||
Maternal age median (IQR) | 881 | 21 (18–26) | 842c | 22 (19–27) | 850c | 22 (19–27) | 855 | 20 (18–25) | 0.67 |
Gestational age (week) median (IQR) | 804 | 38 (36–38) | 729 | 38 (38–40) | 733 | 38 (36–40) | 709 | 38 (36–38) | 0.30 |
Gravidity n (%) | 880 | 842 | 850 | 855 | 0.55 | ||||
1st pregnancy | 319 (36.3) | 315 (37.4) | 278 (32.7) | 343 (40.1) | |||||
2nd pregnancy | 204 (23.2) | 187 (22.2) | 201 (23.7) | 216 (25.3) | |||||
3rd or more | 357 (40.6) | 340 (40.4) | 371 (43.7) | 296 (34.6) | |||||
Malaria prevalence (peripheral blood) n (%) | 829 | 120 (14.5) | 756 | 95 (12.6) | 752 | 123 (16.4) | 748 | 75 (10.0) | 0.21 |
Parasite density; median (IQR) | 120 | 1560 (440–6804) | 95 | 1800 (320–8220) | 123 | 1729 (561–9000) | 75 | 2320 (480–8960) | 0.09 |
% ≤ 2000/µL (n) | 55.0 (66) | 53.7 (51) | 52.0 (64) | 46.7 (35) | |||||
% > 2000/µL (n) | 45.0 (54) | 46.3 (44) | 48.0 (59) | 53.3 (40) | |||||
Gametocyte carriage n (%) | 829 | 3 (0.4) | 756 | 4 (0.5) | 752 | 4 (0.5) | 748 | 2 (0.3) | 0.89 |
Maternal Hb median (IQR) | 828 | 11.2 (10.1–12.2) | 757 | 11.5 (10.4–12.4) | 752 | 11.3 (10.3–12.3) | 749 | 11.2 (10.3–12.2) | 0.30 |
Placenta Malaria n (%)b | 711 | 655 | 674 | 664 | |||||
Acute infection | 7 (1.0) | 14 (2.1) | 13 (1.9) | 11 (1.7) | |||||
Chronic infection | 191 (26.9) | 168 (25.6) | 177 (26.3) | 171 (25.8) | |||||
Past infection | 444 (62.4) | 382 (58.3) | 398 (59.1) | 409 (61.6) | |||||
No infection | 69 (9.7) | 91 (13.9) | 86 (12.8) | 73 (11.0) |
aAdjusted by country
bThe proportion of current (acute and chronic) and past infection vs. no infection, adjusted for country, p = 0.47. Proportion of acute and chronic infection vs. past or no infection, adjusted for country p = 0.52
cOne woman randomized to the ASAQ group was treated with MQAS; in the safety analysis this woman was included in the MQAS group